Viking Therapeutics, Inc. (VKTX) Stock
VKTX has an Alpha Score of 36 out of 100 (weak), computed on Apr 15, 2026 from 3 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported VKTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $62.65M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
What is VKTX's Alpha Score?
How it works →Alpha Score of 36 reflects weak overall profile with moderate momentum, poor value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Apr 15, 2026 · 189 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own VKTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.61M | $62.65M | -4% |
| Citadel Ken Griffin | 952K | $37.12M | -25% |
| Millennium Management Israel Englander | 498K | $19.43M | +99% |
| Point72 Steve Cohen | 473K | $18.46M | NEW |
| Bridgewater Associates Ray Dalio | 88K | $3.43M | +23% |
| Marshall Wace | 43K | $1.67M | -53% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Viking Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Jul 29, 26 | Mancini Marianna | Chief Operating Officer | SELL | 18.2K | $610K |
| Jul 29, 26 | Zante Greg | Chief Financial Officer | SELL | 21.2K | $710K |
| Jul 29, 26 | Lian Brian | President & CEO | SELL | 148.5K | $4.9M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →What are VKTX's key statistics?
Key statistics as of Oct 22, 2026
VKTX price chart
Powered by TradingViewWhat does Viking Therapeutics, Inc. do?
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical trials for obesity, with formulations in both subcutaneous injectable and oral tablet forms. VK2809, another key candidate, targets lipid and metabolic disorders including non-alcoholic steatohepatitis and fatty liver disease. The company also develops VK0214 for the rare disease X-linked adrenoleukodystrophy and is advancing a program of dual amylin and calcitonin receptor agonists for obesity and related metabolic conditions. Headquartered in San Diego, California, Viking leverages its expertise in metabolic biology to address significant unmet medical needs in obesity and metabolic disease management.